D-Dimer/Fibrinogen Ratio Predicts Poor Post-Thrombolysis Stroke Outcomes

This single-center retrospective analysis adds a simple, calculable coagulation-fibrinolysis biomarker to the risk-stratification toolkit for acute ischemic stroke patients receiving intravenous thrombolysis, though its incremental value over established severity scores is modest.

D-dimerfibrinogenD-dimer to fibrinogen ratioDFRacute ischemic strokeintravenous thrombolysisbiomarkerprognosismodified Rankin ScaleNIHSSretrospective cohortneurology Neurology / Neuropharmacology

Background Information

New biomarker DFR predicts poor stroke outcomes post-thrombolysis.

Identifying biomarkers that predict outcomes in acute ischemic stroke (AIS) patients can improve treatment strategies and patient management. The study found that a D-dimer to fibrinogen ratio (DFR) above 0.146 is independently associated with unfavorable outcomes at 3 months in AIS patients undergoing intravenous thrombolysis. This study suggests DFR as a potential biomarker for prognosis in AIS, but further research is necessary to validate its clinical utility given the study's limitations. A higher DFR is linked to worse outcomes in AIS patients treated with thrombolysis.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Zhang X, Fu Y, Lu J

Citation: Zhang X, Fu Y, Lu J Predictive Value of D-Dimer to Fibrinogen Ratio for Unfavorable Outcomes in Acute Ischemic Stroke Patients Undergoing Intravenous Thrombolysis. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2026;32:10760296261468428. doi:10.1177/10760296261468428

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →